MItral Regurgitation Risk Assessment and CLinical modElling (MIRACLE Study)

What this Trial Is About

Mitral regurgitation (MR) is a common heart valve condition linked to higher risks of heart failure and death, especially if severe and untreated. MR can be classified as primary or secondary, and the study aims to understand risk factors for death or heart failure hospitalization in these patients. The MItral Regurgitation Risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study enrolling adults diagnosed with moderate or worse MR during hospital stays to build a clinical model for guiding treatment decisions. Participants undergo thorough echocardiographic exams at the start to measure MR severity, heart function, and pulmonary artery pressure. The study observes these patients over an average of 5 years to collect data on their health outcomes. No treatments are assigned; instead, the study follows patients with MR to identify factors affecting their risk. During the study, participants' health will be monitored with ongoing assessments, focusing on all-cause death, cardiovascular death, and heart failure hospitalizations. The research team reviews these outcomes through the study completion, lasting about 5 years. The data collected aims to improve clinical decisions for managing MR and reducing adverse events.

MItral Regurgitation Risk Assessment and CLinical modElling